

Journal Pre-proof

Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry

Erica J. Brenner, MD, Ryan C. Ungaro, MD, MS, Dr. Richard B. Geary, MBChB, PhD, FRACP, Dr. Gilaad G. Kaplan, MD, MPH, FRCPC, Michele Kissous-Hunt, PA-C, DFAAPA, Dr. James D. Lewis, MD, MSCE, Dr. Siew C. Ng, MD, PhD, Dr. Jean-Francois Rahier, MD, PhD, Dr. Walter Reinisch, MD, Dr. Frank M. Ruemmele, MD, PhD, Dr. Flavio Steinwurz, MD, MSc, MACG, Fox E. Underwood, MSc, Xian Zhang, PhD, Jean-Frederic Colombel, MD, Michael D. Kappelman, MD, MPH

PII: S0016-5085(20)30655-7
DOI: <https://doi.org/10.1053/j.gastro.2020.05.032>
Reference: YGAST 63463

To appear in: *Gastroenterology*
Accepted Date: 8 May 2020

Please cite this article as: Brenner EJ, Ungaro RC, Geary RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier J-F, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel J-F, Kappelman MD, Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry, *Gastroenterology* (2020), doi: <https://doi.org/10.1053/j.gastro.2020.05.032>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 by the AGA Institute



Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry

SHORT TITLE

COVID-19 and IBD

AUTHORS

Erica J. Brenner MD*

*University of North Carolina Department of Pediatric Gastroenterology
Children's Hospital, 101 Manning Dr, Chapel Hill, NC 27514*

Ryan C. Ungaro MD, MS*

*The Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai, 17 E 102nd St 5th Floor, New York, NY 10029*

*Author names in bold designate shared co-first authorship.

Dr. Richard B. Gearry MBChB, PhD, FRACP

University of Otago Department of Medicine

2 Riccarton Avenue, Christchurch Central City, Christchurch 8011, New Zealand

Dr. Gilaad G. Kaplan MD, MPH, FRCPC

University of Calgary, Departments of Medicine and Community Health Sciences

Room 3D03-18, 3280 Hospital Drive NW, Calgary, Alberta, T2N 4Z6, Canada

Michele Kissous-Hunt PA-C, DFAAPA

Mount Sinai Medical Center, 1 Gustave L. Levy Place, New York, NY 10029

Fifth Ave Gl, 1150 Fifth Avenue, Suite 1B, New York, NY 10128

Dr. James D. Lewis MD, MSCE

The University of Pennsylvania

423 Guardian Drive, 720 Blockley Hall, Philadelphia, PA 19104-6021

Dr. Siew C. Ng MD, PhD

Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory

of Digestive Disease, Li Ka Shing Institute of Health Science, The Chinese University of Hong

Kong, Shatin, NT, Hong Kong SAR, The People's Republic of China

Dr. Jean-Francois Rahier MD, PhD

Department of Gastroenterology, Université catholique de Louvain, CHU UCL Namur

5530 Yvoir, Belgium

Dr. Walter Reinisch MD

Medical University of Vienna

Department Internal Medicine III, Division Gastroenterology & Hepatology; Währinger Gürtel 18-

20, A-1090 Vienna, Austria

Dr. Frank M. Ruemmele MD, PhD

Université de Paris, France

Assistance-Publique- Hôpitaux de Paris, Hôpital Necker Enfants Malades, Service de Gastroentérologie pédiatrique, 149 Rue de Sèvres, 75015 Paris, France

Dr. Flavio Steinwurz MD, MSc, MACG

Hospital Israelita Albert Einstein

Av. Albert Einstein, 627 - Jardim Leonor, São Paulo - SP, 05652-900, Brazil

Fox E. Underwood MSc

*University of Calgary, Departments of Medicine and Community Health Sciences
Room HSC 1745, 2500 Hospital Drive NW, Calgary, Alberta, T2N 1N4, Canada*

Xian Zhang PhD

*University of North Carolina Department of Gastroenterology
101 Manning Dr, Chapel Hill, NC 27514*

Jean-Frederic Colombel MD

The Henry D. Janowitz Division of Gastroenterology

Icahn School of Medicine at Mount Sinai, 17 E 102nd St 5th Floor, New York, NY 10029

Michael D. Kappelman MD, MPH

*University of North Carolina Department of Pediatric Gastroenterology
Children's Hospital, 101 Manning Dr, Chapel Hill, NC 27514*

CORRESPONDING AUTHORS

Erica J. Brenner MD

919-966-2435

Erica.Brenner@unchealth.unc.edu

Ryan C. Ungaro MD, MS

212-241-4514

Ryan.ungaro@mssm.edu

GRANT SUPPORT

This work was funded by CTSA grant number UL1TR002489 and K23KD111995-01A1 (to RCU).

ABBREVIATIONS

AZA (azathioprine)*

CAD (coronary artery disease)*

CKD (chronic kidney disease)*

COPD (chronic obstructive pulmonary disease)*

COVID-19 (Coronavirus disease 2019)

CD (Crohn's disease)

GI (Gastrointestinal)

IBD (inflammatory bowel disease)

ICU (intensive care unit)

MERS (Middle East Respiratory Syndrome)

MTX (Methotrexate)*

NAFLD (non-alcoholic fatty liver disease)*

PSC (primary sclerosing cholangitis)*

SARS (Severe Acute Respiratory Syndrome)

SMR (standardized mortality ratio)

SECURE-IBD (Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease)

TNF (Tumor Necrosis Factor)

UC (ulcerative colitis)

5-ASA (5-aminosalicylate)

6-MP (6-Mercaptopurine)

*Abbreviations used in tables only

DISCLOSURES

Erica J. Brenner MD*

No conflicts of interest.

Ryan C. Ungaro MD, MS*

Grant Support: RCU is supported by an NIH K23 Career Development Award (K23KD111995-01A1).

Financial Disclosures: RCU has served as an advisory board member or consultant for Eli Lilly, Janssen, Pfizer, and Takeda; research support from AbbVie, Boehringer Ingelheim, and Pfizer.

*These authors contributed equally to this manuscript.

Dr. Richard B. Geary MBChB

Speaker fees and Scientific Advisory Boards for AbbVie and Janssen

Dr. Gilaad G. Kaplan MD, MPH, FRCPC

Conflicts of interest: Dr. Kaplan has received honoraria for speaking or consultancy from Abbvie, Janssen, Pfizer, and Takeda. He has received research support from Ferring, Janssen,

Abbvie, GlaxoSmith Kline, Merck, and Shire. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. 7 Sept. 2018.

Michele Kissous-Hunt PA-C, DFAAPA

Speaker/consultant for Abbvie, Janssen, Takeda.

Dr. James Lewis MD, MSCE

Dr. Lewis reports personal fees from Johnson & Johnson Consumer Inc, grants, personal fees and other from Takeda Pharmaceuticals, personal fees and non-financial support from AbbVie, grants and personal fees from Janssen Pharmaceuticals, personal fees from Eli Lilly and Company, personal fees from Samsung Bioepis, personal fees from UCB, personal fees from Bristol-Myers Squibb, grants and personal fees from Nestle Health Science, personal fees from Bridge Biotherapeutics, personal fees from Celgene, personal fees from Merck, personal fees and other from Pfizer, personal fees from Gilead, personal fees from Arena Pharmaceuticals, personal fees from Protagonist Therapeutics, outside the submitted work

Dr. Siew C. Ng MD, PhD

Conflicts of interest: Dr. Ng has received honoraria for speaking or consultancy from Abbvie, Janssen, Ferring, Tillotts and Takeda. She has received research support from Ferring and Abbvie.

Dr. Jean-Francois Rahier MD, PhD

Jean-François Rahier has received lecture fees from AbbVie, MSD, Takeda, Pfizer, Ferring, and Falk, consulting fees from AbbVie, Takeda, Hospira, Mundipharma, MSD, Pfizer, GlaxoSK, and Amgen, and research support from Takeda and AbbVie

Dr. Walter Reinisch MD

Walter Reinisch has served as a speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult. He has been a consultant for Abbott Laboratories, Abbvie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmbH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Roberts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC. He has been

as an advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos,

Tigenix, UCB, Zealand, Zyngenia, and 4SC. He has received research funding from Abbott Laboratories, Abbvie, Aesca, Centocor, Falk Pharma GmbH, Immundiagnosotik, and MSD.

Dr. Frank Ruemmele

Received consultation fee, research grant, or honorarium from Janssen, Pfizer, Abbvie, Takeda, Celgene, Nestlé Health Science, Nestlé Nutrition Institute.

Dr. Flavio Steinwurz MD, MSc, MACG

Speaker and consultant for: AbbVie, Eurofarma, Ferring, Janssen, Pfizer, Sanofi, Takeda, and UCB.

Fox E. Underwood MSc

No conflicts of interest.

Xian Zhang PhD

No conflicts of interest.

Jean-Frederic Colombel, MD

Dr. Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, Tigenix, Viela bio; and hold stock options in Intestinal Biotech Development and Genfit.

Michael D. Kappelman MD, MPH

MDK has consulted for Abbvie, Janssen, and Takeda, is a shareholder in Johnson & Johnson, and has received research support from Abbvie and Janssen.

WRITING ASSISTANCE

The manuscript was written by the authors themselves, as specified in Specific Author

Contributions below. There were no additional individuals who provided writing assistance.

SPECIFIC AUTHOR CONTRIBUTIONS

Erica J. Brenner MD*

Conceptualization, formal analysis, investigation, methodology, writing – original draft.

Ryan C. Ungaro MD*

Conceptualization, formal analysis, investigation, funding acquisition, methodology, writing – original draft.

*These authors contributed equally to this manuscript.

Dr. Richard B. Geary MBChB
Formal analysis, writing – review & editing

Dr. Gilaad G. Kaplan MD
Formal analysis, writing – review & editing

Michele Kissous-Hunt PA-C
Formal analysis, writing – review & editing

Dr. James D. Lewis MD
Formal analysis, writing – review & editing

Dr. Siew C. Ng MD
Formal analysis, writing – review & editing

Dr. Jean-Francois Rahier MD
Formal analysis, writing – review & editing

Dr. Walter Reinisch MD
Formal analysis, writing – review & editing

Dr. Frank M. Rummelle MD
Formal analysis, writing – review & editing

Dr. Flavio Steinwurz MD
Formal analysis, writing – review & editing

Fox E. Underwood MSc
Visualization, software, writing - review & editing

Xian Zhang PhD
Data curation, formal analysis, methodology, writing - review & editing

Jean-Frederic Colombel MD
Conceptualization, formal analysis, investigation, methodology, writing – original draft, supervision

Michael D. Kappelman MD
Conceptualization, formal analysis, investigation, methodology, writing – original draft, funding acquisition, supervision

FUNDING

This work was funded by CTSA grant number UL1TR002489 and K23KD111995-01A1 (to RCU). The study sponsor (National Institutes of Health) had no role in the collection, analysis, and interpretation of data.

ACKNOWLEDGEMENTS

We acknowledge the physicians and other healthcare providers worldwide who have reported cases to the SECURE-IBD database and the organizations who supported or promoted the SECURE-IBD database (Reporter names available at www.covidibd.org/reporter-acknowledgment/. See Table S4 for organization names).

ABSTRACT

Background and Aims: The impact of Coronavirus disease 2019 (COVID-19) on patients with inflammatory bowel disease (IBD) is unknown. We sought to characterize the clinical course of COVID-19 among IBD patients and evaluate the association between demographics, clinical characteristics, and immunosuppressant treatments on COVID-19 outcomes.

Methods: Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is a large, international registry created to monitor outcomes of IBD patients with confirmed COVID-19. We calculated age-standardized mortality ratios (SMRs) and utilized multivariable logistic regression to identify factors associated with severe COVID-19, defined as intensive care unit admission, ventilator use, and/or death.

Results: 525 cases from 33 countries were reported (Median age 43 years, 53% men). Thirty-seven patients (7%) had severe COVID-19, 161 (31%) were hospitalized, and 16 patients died (3% case fatality rate). SMRs for IBD patients were 1.8 (95% confidence interval [CI] 0.9-2.6), 1.5 (95% CI 0.7-2.2), and 1.7 (95% CI 0.9-2.5) relative to data from China, Italy, and the US, respectively. Risk factors for severe COVID-19 among IBD patients included increasing age (adjusted odds ratio [aOR] 1.04, 95% CI 1.01-1.02), ≥ 2 comorbidities (aOR 2.9, 95% CI 1.1-7.8), systemic corticosteroids (aOR 6.9, 95% CI 2.3-20.5), and sulfasalazine or 5-aminosalicylate use (aOR 3.1, 95% CI 1.3-7.7). TNF antagonist treatment was not associated with severe COVID-19 (aOR 0.9, 95% CI 0.4-2.2).

Conclusions: Increasing age, comorbidities, and corticosteroids are associated with severe COVID-19 among IBD patients, although a causal relationship cannot be definitively established. Notably, TNF antagonists do not appear to be associated with severe COVID-19.

Keywords: inflammatory bowel disease, Crohn's disease, ulcerative colitis, COVID-19

INTRODUCTION

Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in December 2019 and has rapidly spread throughout the world leading to an international pandemic.¹ Although most cases of COVID-19 are mild, the disease can become severe and result in hospitalization, respiratory failure, or death with reported case fatality rates ranging from 2.3% to 7.2%.^{2, 3} To date, the most frequently identified risk factors for severe COVID-19 have been age, cardiovascular disease, chronic lung conditions, obesity, and diabetes.^{2, 4} In a recent report from the United States, 78% of patients requiring intensive care unit (ICU) admission had at least one underlying comorbidity.⁴

Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory conditions of the gastrointestinal tract affecting millions of people worldwide.⁵⁻⁷ Patients with IBD and related rheumatologic, dermatologic, and neurologic auto-inflammatory conditions frequently require treatment with immunosuppressant medications which can increase the risk of infection.⁶⁻¹⁰ Corticosteroids, immunomodulators (thiopurines, methotrexate), biologics, and janus-kinase inhibitors, commonly used to treat chronic auto-inflammatory conditions, have been associated with higher rates of serious viral and bacterial infections including influenza and pneumonia.¹¹⁻¹⁵ Yet, it is also possible that some forms of immune suppression may blunt the excessive immune response/cytokine storm characteristic of severe COVID-19 infection and consequently reduce mortality, as suggested by emerging case reports of anti-IL-6 therapy.^{16, 17}

Little is known about the impact of COVID-19 on patients with chronic auto-inflammatory diseases such as IBD, particularly those who require systemic immunosuppressant medications. An initial report of COVID-19 among 1,099 patients in China included only two persons with immune deficiency.¹⁸ A subsequent report found that cancer patients had a higher risk of severe COVID-19, but this conclusion was based on only 16 patients.¹⁹ In Italy, Mazza et al reported a case of COVID-19 pneumonia leading to death in a patient with severe acute ulcerative colitis treated with systemic corticosteroids.²⁰

In order to provide better guidance to patients and their health care providers and to inform strategies for prevention of COVID-19 and medication management, more data are urgently needed regarding the impact of IBD and treatments on COVID-19 outcomes. In the present work, we report on the clinical course of COVID-19 and risk factors for adverse outcomes in a large cohort of patients with IBD collected through an international registry.

MATERIALS AND METHODS

Case identification and data collection

We created the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) database to monitor outcomes of COVID-19 occurring in pediatric and adult IBD patients. SECURE-IBD is an international, collaborative effort, endorsed and promoted by the International Organization for the Study of Inflammatory Bowel Disease (IOIBD), the Crohn's & Colitis Foundation (US), the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), the European Crohn's and Colitis Organisation (ECCO), the Pan American Crohn's and Colitis Organization (PANCCO),

the Asian Organization of Crohn's & Colitis (AOCC) and several regional/national organizations (Table S4).

Physicians and other health care providers were encouraged to voluntarily report all cases of Polymerase Chain Reaction (PCR)-confirmed COVID-19 occurring in IBD patients, regardless of severity. To foster international collaboration and promote transparency, we developed a project website (www.covidibd.org) to acknowledge the contributions of individual reporters and share crude, aggregate data along with an interactive web-based map displaying the geographic location of reported cases (<https://covidibd.org/map/>).

We instructed health care providers to report cases after a minimum of 7 days from symptom onset and sufficient time had passed to observe the disease course through resolution of acute illness or death. In the event that a patient's status changed after reporting or if there were concerns about data accuracy, we instructed reporters to re-report and contact the research team to remove their initial entry.

We utilized REDCap (Research Electronic Data Capture), a secure, web-based electronic data capture tool hosted at the University of North Carolina at Chapel Hill to collect and manage study data. Health care providers recorded the following information: age, country of residence, state of residence (if applicable), year of COVID-19 diagnosis, name of center/practice/physician providing care, sex, race, ethnicity, height, weight, patient's diagnosis (CD, UC, or inflammatory bowel disease unclassified, IBD-U), disease activity (as defined by physician global assessment [PGA]), medications at time of COVID-19 diagnosis, whether the patient was hospitalized, gastrointestinal (GI) symptoms related to COVID-19, COVID-19 treatments used, and whether the patient died of COVID-19 or complications related to COVID-

19. For hospitalized patients, the name of hospital, length of stay, need for ICU, and need for a ventilator were additionally recorded.

QGIS 3.4.4 (www.osgeo.org) was used to create a choropleth map of the number of reported cases of IBD stratified by four classes using Jenks Natural Breaks.²¹ ArcGIS Pro 2.4.1 and ArcGIS Online (www.esri.com/en-us/home) were used to create an interactive global map (<https://covidibd.org/map/>) that visualizes patients with IBD diagnosed with COVID-19, as well as their clinical course and characteristics.

The Pediatric IBD Porto group of the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) implemented a parallel reporting system at 102 affiliated sites. Recently reported preliminary data from this consortium are included in the analyses described below.²²

Quality control

We removed all known duplicate or erroneous reports. We identified additional potential duplicate records based on matching age, sex, IBD disease type, country, and state (U.S. only), and reviewed these manually. Reports from non-valid email addresses were flagged as potential errors and we performed a Google search of reporters and practice locations to confirm legitimacy of reports.

Statistical Analysis

We used descriptive statistics to summarize the basic demographic and clinical characteristics of the study population. We summarized continuous variables using means and standard

deviations. We expressed categorical variables as proportions. Comorbidities were collapsed into the following categories: cardiovascular disease, diabetes, hypertension, stroke, lung disease, kidney disease, liver disease, and cancer.

We analyzed a variety of COVID-19 outcomes, including outpatient care only, hospitalization, ICU or ventilator requirement, and death from COVID-19 or related complications. Crude data are provided for the overall study population, and stratified by a variety of demographic and clinical characteristics. To understand the impact of IBD on case fatality, we computed expected and observed deaths and age-standardized mortality ratios (SMR) utilizing published age-stratified COVID-19 case fatality rates from China and Italy^{2, 23} and publically available data from the U.S.^{24, 25}

Multivariable logistic regression estimated the independent effects of age, sex, disease (CD vs UC/IBD-U), disease activity, smoking, BMI ≥ 30 , and number of comorbidities (0, 1, ≥ 2) on the primary outcome of severe COVID-19, defined as a composite of ICU admission, ventilator use, and/or death, consistent with existing COVID-19 literature.¹⁸ Models also included tumor necrosis factor (TNF) antagonist use (versus not) and sulfasalazine/5-aminosalicylate (5-ASA) use (versus not) as these were the two most commonly reported medication classes and systemic corticosteroid use (versus not) based on increased risk of infectious complications based on prior literature and crude data. A secondary outcome was the composite of any hospitalization and/or death. We also analyzed death as a separate endpoint. We reported adjusted odds ratios (aOR) and 95% confidence intervals (CI) for each demographic or disease characteristic.

We also performed a series of exploratory sub-analyses. We compared TNF antagonist monotherapy versus combination therapy with immunomodulators (6-mercaptopurine [6MP],

azathioprine, or methotrexate), controlling for the above demographic and clinical factors as well as the use of systemic corticosteroids and 5-ASA/sulfasalazine. In addition, given the surprising association between 5-ASA/sulfasalazine use and more severe COVID outcomes in our main analyses, we performed a sub-analysis to directly compare the effects of TNF antagonists versus 5-ASA/ sulfasalazine, controlling for the above factors as well as use of immunomodulators. The primary outcome of these exploratory analyses was the composite of any hospitalization and/or death. The number of events was too sparse to evaluate other outcomes. All data were prepared and analyzed using SAS v 9.3 (SAS Institute, Cary, North Carolina). Two-sided p values < 0.05 were considered statistically significant.

Ethical Considerations

Each SECURE-IBD survey item met criteria for de-identified data, in accordance with the HIPAA Safe Harbor De-Identification standards. The UNC-Chapel Hill Office for Human Research Ethics has determined that the storage and analysis of de-identified data for this project does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102] and does not require IRB approval.

FINDINGS

At the time of this writing, a total of 525 cases were reported to the SECURE-IBD database from 33 different countries and 28 states within the United States (Figures 1 and 2; Tables S1 and S2). Demographic, clinical, and IBD treatment related characteristics are summarized in Table 1. The median age was 41 years, with a range from 5 to ≥ 90 years, and there was a slight predominance of males (52.6%). Most cases were reported in whites (84.2%). Ethnicity was reported as Hispanic/Latino in 14.3% of cases (Table 1).

The majority of patients had CD (59.4%), and IBD disease activity by PGA was classified as remission in 58.9% of cases. The most common class of IBD treatment was TNF antagonist therapy (43.4% overall, 33.5% monotherapy and 9.9% combination therapy with azathioprine, 6-mercaptopurine, or methotrexate). Use of other medications is described in Table 1. Most patients (63.4%) had no comorbidities other than IBD; 21.0% had one, 6.7% had two, and 5.5% had three or more. Four percent of the cohort reported using tobacco and/or electronic cigarettes (Table 1).

Crude outcome data are summarized in Table 2 for the overall study population, stratified by a variety of demographic and clinical characteristics. Overall, 161 patients required hospitalization (31%), 24 stayed in an ICU (5%), and 21 used a ventilator (4%). The primary outcome (ICU/ventilator/death) was observed in 37/525 (7%) of patients. Of these, 20/101 (20%) occurred in patients ≥ 60 years of age versus 0/29 pediatric cases (< 20 years). Only 3 pediatric patients (10%) required hospitalization; none required ICU or ventilator support. Patients with more comorbidities also experienced a higher proportion of adverse outcomes. Nine of 37 patients on systemic corticosteroids (24%) experienced the primary endpoint. Additional outcome data, stratified by medication use, is shown in Table 2.

Sixteen deaths (3% of reported cases) are summarized in Table S3. Eight deaths (50%) occurred in patients ≥ 70 years of age. No deaths occurred in patients < 30 years of age. Most deaths had comorbidities, including eight with cardiovascular disease. The age-standardized SMRs for the SECURE-IBD population relative to China, Italy, and the U.S. were 1.8 (95%

confidence interval [CI] 0.9-2.6), 1.5 (95% CI 0.7-2.2), and 1.7 (95% CI 0.9-2.5) respectively (Tables 3 and 4).

On multivariable analysis, increasing age (aOR 1.04, 95% CI 1.01-1.06), ≥ 2 comorbidities (aOR 2.9, 95% CI 1.1-7.8), systemic corticosteroids (aOR 6.9, 95% CI 2.3-20.5), and 5-ASA/sulfasalazine use (aOR 3.1, 95% CI 1.3-7.7) were positively associated with the primary endpoint after controlling for all other covariates listed in Table 5. No significant association was seen between TNF antagonist use and the primary endpoint (aOR 0.9, 95% CI 0.4-2.2). Similar associations were observed for our secondary outcomes, although TNF antagonist use was inversely associated with the outcome of hospitalization or death while only age and systemic corticosteroid use were positively associated with the outcome of death.

In our exploratory analyses, we found that TNF antagonist combination therapy, compared to monotherapy, was positively associated with the outcome of hospitalization or death (aOR 5.0, 95% CI 2.0-12.3), after adjusting for clinical and demographic variables and use of systemic corticosteroids and 5-ASA/sulfasalazine. Compared to TNF antagonists, 5-ASA/sulfasalazine was positively associated with the outcome of hospitalization or death (aOR 3.8, 95% CI 1.7-8.5).

DISCUSSION

We report the development of an international, physician-driven, reporting system to study the natural history of COVID-19 in pediatric and adult patients with IBD. Given the expanding knowledge that persons with comorbidities are disproportionately affected by COVID-19, there

is an urgent need to evaluate this emerging infection on patients with systemic, auto-inflammatory conditions such as inflammatory bowel disease (IBD), many of whom are treated with immunosuppressive medications. To date, no large, international reports describing the clinical course of COVID-19 in these patient populations have been published. Based on results from 525 IBD patients from 33 countries, we observed an overall case fatality rate of 3% with 7% of reported cases experiencing a composite outcome of ICU admission, ventilator support, and/or death. Strong risk factors for adverse COVID-19 outcomes were older age, number of comorbidities, and use of systemic corticosteroids. Unexpectedly, use of 5-ASA/sulfasalazine was also associated with more severe COVID-19. Reassuringly, TNF antagonist biologic therapy was not an independent risk factor for more severe COVID-19.

In this international IBD population, we observed an age-standardized mortality ratio of approximately 1.5 to 1.8, as compared to the general populations of China, Italy, and the U.S. with confidence intervals crossing the null. We note no deaths occurred in the 29 reported cases occurring in patients <20 years of age, extending the findings of an earlier case series suggesting a milder course of COVID-19 in pediatric patients.²² In contrast, 50% of deaths occurred in patients over 70 years of age and 50% of patients who died had cardiovascular comorbidities.

The strong positive association between systemic corticosteroid use and our primary and secondary outcomes is consistent with extensive prior literature in IBD and other auto-inflammatory conditions describing the infectious complications of corticosteroid use as well as more recent data indicating that corticosteroids are not beneficial, and may even be harmful, in the treatment of coronavirus and similar viruses (MERS, SARS, etc.).²⁶ Forty-three percent of

our cohort was exposed to TNF antagonist medications. In the adjusted analysis of our primary outcome, we observed no association between TNF antagonist use and severe COVID-19. As TNF antagonists are the most commonly prescribed biologic therapy for patients with IBD, these initial findings should be reassuring to the large number of patients receiving TNF antagonist therapy and support their continued use during this current pandemic. In our exploratory subgroup analysis, we observed a higher risk of hospitalization and/or death with TNF antagonist combination therapy versus monotherapy, consistent with prior studies of other infectious complications.¹² Given the overall effect estimate of TNF antagonists (combination and monotherapy combined) in our primary model was 0.9, one can hypothesize that TNF antagonist monotherapy may have a protective effect against severe COVID-19, as suggested in a recent commentary.²⁷

We observed a higher risk of our primary outcome in patients exposed to 5-ASA/sulfasalazine. This finding persisted after controlling for age, comorbidities, IBD disease characteristics, corticosteroid use, and other factors. Furthermore, in a direct comparison, we observed that 5-ASA/sulfasalazine treated patients fared worse than those treated with TNF inhibitors. Although we cannot exclude unmeasured confounding, further exploration of biological mechanisms is warranted. Conversely, although the number of reported cases exposed to other IBD treatments is currently small, it is worth noting that 51/55 (93%) patients treated with anti-IL12/23 required outpatient care only and none died.

The strengths of this study include the robust, worldwide collaboration that enabled us to assemble clinical data on a large, geographically diverse sample of pediatric and adult IBD patients and rapidly define the course of COVID-19 in this population. The reporting directly by

physicians or their trained medical staff strengthens the validity of these data. Although our study sample is diverse in terms of age, geography, race, and other factors, we acknowledge the possibility of reporting bias. Reported cases may over-represent more severe COVID-19 patients who come to the attention of their provider and patients in areas with readily available COVID-19 testing. Conversely, our sample may under-represent those severely ill patients who may be hospitalized at an outside hospital or die without their physician's awareness. The registry includes only confirmed cases of COVID-19 in accordance with other reporting initiatives from national authorities and the World Health Organization,^{2, 4, 18} though we recognize many patients with suspected infection are never tested. Although we adjusted for many factors such as age, comorbidities, and IBD disease type and severity, we acknowledge the possibility of unmeasured confounding. Additional research is needed to further evaluate causality between the use of corticosteroids and other medications and COVID-19 outcomes. Finally, we computed age-standardized mortality ratios using case fatality rates reported from China, Italy, and the U.S., yet our study sample arose from 31 different countries. Given the profound effects of age on COVID-19 related mortality, we believe it was useful to standardize to existing data. That our SMR estimates were roughly equivalent when standardizing to Chinese, Italian, or U.S. data suggests the overall validity of this approach.

In summary, older age, increased number of comorbidities and systemic corticosteroid use among patients with IBD are strong risk factors for adverse COVID-19 outcomes. Maintaining remission with steroid-sparing treatments will be important in managing patients with IBD through this pandemic. It appears that TNF antagonist therapy is not associated with severe COVID-19, providing reassurance that patients can continue TNF antagonist therapy.

REFERENCES

1. Morens DM, Daszak P, Taubenberger JK. Escaping Pandora's Box - Another Novel Coronavirus. *N Engl J Med* 2020;382:1293-1295.
2. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *Jama* 2020.
3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *Jama* 2020.
4. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:382-386.
5. **Ng SC**, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, **Kaplan GG**. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* 2018;390:2769-2778.
6. Torres J, Mehandru S, Colombel JF, et al. Crohn's disease. *Lancet* 2017;389:1741-1755.
7. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. *Lancet* 2017;389:1756-1770.
8. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol* 2018;113:481-517.
9. **Matsuoka K, Kobayashi T**, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. *J Gastroenterol* 2018;53:305-353.
10. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* 2014;8:443-68.

11. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. *J Crohns Colitis* 2013;7:107-12.
12. Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. *Gastroenterology* 2018;155:337-346.e10.
13. Long MD, Martin C, Sandler RS, et al. Increased risk of pneumonia among patients with inflammatory bowel disease. *Am J Gastroenterol* 2013;108:240-8.
14. Ma C, Lee JK, Mitra AR, et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. *Aliment Pharmacol Ther* 2019;50:5-23.
15. Tinsley A, Williams E, Liu G, et al. The Incidence of Influenza and Influenza-related Complications in Inflammatory Bowel Disease Patients across the United States: 1833. *American Journal of Gastroenterology* 2013;108.
16. **Michot JM, Albies L**, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. *Annals of Oncology* 2020.
17. Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. *Blood Advances* 2020;4:1307-1310.
18. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020.
19. **Liang W, Guan W, Chen R, Wang W**, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol* 2020;21:335-337.
20. Mazza S, Sorce A, Peyvandi F, et al. A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis. *Gut* 2020;gutjnl-2020-321183.
21. Jenks G. The data model concept in statistical mapping. *Int Yearb Carto* 1967;7:186–190.

22. Turner D, Huang Y, Martín-de-Carpi J, et al. COVID-19 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto group of ESPGHAN. *Journal of Pediatric Gastroenterology and Nutrition* 9000; Publish Ahead of Print.
23. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2020;41:145-151.
24. Centers for Disease Control and Prevention. Coronavirus Disease 2019 Cases in U.S. <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html>. Published April 16, 2020. Accessed April 17, 2020.
25. Centers for Disease Control and Prevention. Provisional Death Counts for Coronavirus Disease (COVID-19). <https://www.cdc.gov/nchs/nvss/vsrr/COVID19/>. Published April 17, 2020. Accessed April 17, 2020.
26. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020;395:473-475.
27. Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. *Lancet* 2020.

Author names in bold designate shared co-first authorship.

Journal Pre-proof

TABLES

Table 1. Demographics and clinical characteristics of SECURE-IBD cohort (Total N = 525)1

Characteristic^{a,b}	
Age in years, mean (SD)	42.9 (18.2)
Sex, n (%) ^c	
Male	276 (52.6)
Female	243 (46.3)
Missing	6 (1.1)
Race, n (%) ^d	
Reported at least selected one race (including other/unknown)	523 (99.6)
White	442 (84.2)
Black or African American	26 (5.0)
American Indian/Native Alaskan	1 (0.2)
Asian	14 (2.7)
Native Hawaiian/Pacific Islander	0 (0.0)
Other	47 (9.0)
Unknown	13 (2.5)
Hispanic/Latino, n (%)	
Yes	75 (14.3)
No	350 (66.7)
Unknown	45 (8.6)
Missing	55 (10.5)
Disease type, n (%)	
Crohn's disease	312 (59.4)
Ulcerative Colitis	203 (38.7)
IBD-unspecified	7 (1.3)
Missing	3 (0.6)
IBD disease activity, n (%) ^e	

Remission	309 (58.9)
Mild	100 (19.0)
Moderate	76 (14.5)
Severe	24 (4.6)
Unknown	4 (0.8)
Missing	12 (2.3)
IBD Medication, n (%) [†]	
Any medication	494 (94.1)
Sulfasalazine/mesalamine	117 (22.3)
Budesonide	18 (3.4)
Oral/parenteral steroids	37 (7.0)
6MP/azathioprine monotherapy ^g	53 (10.1)
Methotrexate monotherapy ^g	5 (1.0)
Anti-TNF without 6MP/AZA/MTX	176 (33.5)
Anti-TNF + 6MP/AZA/MTX	52 (9.9)
Anti-integrin	50 (9.5)
IL-12/23 inhibitor	55 (10.5)
JAK inhibitor	8 (1.5)
Other IBD medication	22 (4.2)
Comorbid conditions, n (%)	
Any condition	192 (36.6)
Cardiovascular disease (CAD, heart failure, arrhythmia, etc.)	38 (7.2)
Diabetes	29 (5.5)
Lung disease (asthma, COPD, etc.)	44 (8.4)
Hypertension	63 (12.0)
Cancer	10 (1.9)
History of stroke	4 (0.8)
Chronic renal disease (CKD, etc.)	10 (1.9)
Chronic liver disease (PSC, NAFLD, cirrhosis, etc.)	26 (5.0)
Other	53 (10.1)

Current smoker ^h	23 (4.4)
Gastrointestinal symptoms, n (%)	
Any increase in baseline IBD symptoms	161 (30.7)
Abdominal pain	44 (8.4)
Diarrhea	134 (25.5)
Nausea	30 (5.7)
Vomiting	17 (3.2)
Other	13 (2.5)
Medications and/or investigational therapies used in COVID-19 treatment, n (%)	
Any medication	146 (27.8)
Remdesivir	2 (0.4)
Chloroquine	14 (2.7)
Hydroxychloroquine	98 (18.7)
Oseltamivir	6 (1.1)
Lopinavir/ritonavir	28 (5.3)
Tocilizumab	5 (1.0)
Corticosteroids ⁱ	12 (2.3)
Other	67 (12.8)
No medications and/or investigational therapies were used	321 (61.1)
Unknown	16 (3.0)
Died of COVID-10 or other complications caused by or contributed to by COVID-19, n (%)	
Yes	16 (3.0)
No	498 (94.9)
Unknown	8 (1.5)
Missing	3 (0.6)
Emergency Room, n (%)	
Yes	199 (37.9)
No	312 (59.4)
Unknown	9 (1.7)

Missing	5 (1.0)
Hospitalized, n (%)	
Yes	161 (30.7)
No	363 (69.1)
Unknown	1 (0.2)
Hospital length of stay in days, mean (SD)	8.5 (6.9)
ICU, n (%)	24 (4.6)
Ventilator, n (%)	21 (4.0)
ICU and/or ventilator use, n (%)	27 (5.1)

^aUnless otherwise specified, percentages do not include missing values or "unknown." For all characteristics, less than 4% of data was missing and unknown, respectively, for each category.

^bPercentages and n from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variables.

^cNo individuals identifying as other sex were reported to the database.

^dIndividual cases could belong to ≥ 1 race, so percentages may sum to $>100\%$.

^eBy physician global assessment (PGA) at time of COVID-19 infection

^fAt time of COVID-19 infection. Medication categories are not mutually exclusive unless otherwise noted.

^gMonotherapy indicates no concomitant TNF antagonist, anti-integrin, anti-IL12/23, or JAK inhibitor

^hCurrent smoker defined as current tobacco and/or e-cigarette use

ⁱStarted specifically for COVID-19 treatment, not for IBD care

Abbreviations: SECURE-IBD = Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease; COVID-19 = Coronavirus Disease 2019; TNF = Tumor Necrosis Factor; 6MP = 6-mercaptopurine; AZA = azathioprine; MTX = methotrexate; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; PSC = primary sclerosing cholangitis; NAFLD = non-alcoholic fatty liver disease; GI = gastrointestinal

Table 2. Outcomes by demographic, clinical, and treatment characteristics of SECURE-IBD cohort

Characteristic ^{a,b}	Total N	Outpatient only, n (%)	Hospitalized, n (%)	ICU, n (%)	Ventilator, n (%)	Death, n (%)	ICU/Ventilator/Death, n (%)
Overall	525	363 (69)	161 (31)	24 (5)	21 (4)	16 (3)	37 (7)
Age							
0-9 years	3	3 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
10-19 years	26	23 (88)	3 (12)	0 (0)	0 (0)	0 (0)	0 (0)
20-29 years	116	93 (80)	23 (20)	2 (2)	1 (1)	0 (0)	2 (2)
30-39 years	108	87 (81)	20 (19)	4 (4)	2 (2)	1 (1)	4 (4)
40-49 years	95	64 (67)	31 (33)	4 (4)	3 (3)	2 (2)	5 (5)
50-59 years	74	45 (61)	29 (39)	3 (4)	5 (7)	2 (3)	6 (8)
60-69 years	54	30 (56)	24 (44)	10 (19)	9 (17)	3 (6)	11 (20)
70-79 years	24	7 (29)	17 (71)	1 (4)	1 (4)	2 (8)	3 (13)
>=80 years	23	9 (39)	14 (61)	0 (0)	0 (0)	6 (26)	6 (26)
Sex							
Male	276	183 (66)	93 (34)	12 (4)	9 (3)	11 (4)	21 (8)
Female	243	175 (72)	67 (28)	12 (5)	12 (5)	5 (2)	16 (7)
Disease type							
Crohn's disease	312	228 (73)	83 (27)	12 (4)	9 (3)	5 (2)	16 (5)
Ulcerative Colitis/unspecified	210	133 (63)	77 (37)	12 (6)	12 (6)	11 (5)	21 (10)
IBD Disease Activity ^c							
Remission	309	232 (75)	76 (25)	12 (4)	14 (5)	8 (3)	19 (6)
Mild	100	70 (70)	30 (30)	2 (2)	1 (1)	4 (4)	5 (5)
Moderate/Severe	100	52 (52)	48 (48)	9 (9)	5 (5)	3 (3)	12 (12)
Unknown	16	9 (56)	7 (44)	1 (6)	1 (6)	1 (6)	1 (6)
Smoking							
Current smoker	23	12 (52)	11 (48)	0 (0)	0 (0)	1 (4)	1 (4)
Non-smoker	502	351 (70)	150 (30)	24 (5)	21 (4)	15 (3)	36 (7)
Comorbidities							
0	351	272 (77)	79 (23)	11 (3)	8 (2)	4 (1)	13 (4)

1	110	74 (67)	35 (32)	4 (4)	4 (4)	4 (4)	8 (7)
2	35	10 (29)	25 (71)	4 (11)	5 (14)	3 (9)	7 (20)
3+	29	7 (24)	22 (76)	5 (17)	4 (14)	5 (17)	9 (31)
IBD medication ^d							
Sulfasalazine/ mesalamine	117	60 (51)	57 (49)	12 (10)	12 (10)	9 (8)	20 (17)
Budesonide	18	9 (50)	9 (50)	3 (17)	3 (17)	1 (6)	3 (17)
Oral/parenteral steroids	37	11 (30)	26 (70)	6 (16)	5 (14)	4 (11)	9 (24)
6MP/azathioprine monotherapy ^e	53	29 (55)	24 (45)	3 (6)	3 (6)	1 (2)	3 (6)
Methotrexate monotherapy ^e	5	2 (40)	3 (60)	0 (0)	0 (0)	0 (0)	0 (0)
Anti-TNF without 6MP/AZA/MTX	176	150 (85)	25 (14)	3 (2)	1 (1)	1 (1)	4 (2)
Anti-TNF + 6MP/AZA/MTX	52	32 (62)	20 (38)	4 (8)	2 (4)	2 (4)	5 (10)
Anti-integrin	50	34 (68)	16 (32)	2 (4)	3 (6)	0 (0)	3 (6)
IL-12/23 inhibitor	55	51 (93)	4 (7)	1 (2)	0 (0)	0 (0)	1 (2)
JAK inhibitor	8	7 (88)	1 (13)	1 (13)	1 (13)	1 (13)	1 (13)
Other IBD medication	22	13 (59)	9 (41)	1 (5)	1 (5)	0 (0)	1 (5)

^aUnless otherwise specified, percentages do not include missing values or "unknown." For all characteristics, less than 4% of data was missing and unknown, respectively, for each category.

^bPercentages and n from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variables.

^cBy physician global assessment (PGA) at time of COVID-19 infection

^dAt time of COVID-19 infection. Medication categories are not mutually exclusive unless otherwise noted.

^eMonotherapy indicates no concomitant TNF antagonist, anti-integrin, anti-IL12/23, or JAK inhibitor

Abbreviations: COVID-19 = Coronavirus Disease 2019; ICU = Intensive Care Unit; TNF = Tumor Necrosis Factor; 6MP = 6-mercaptopurine; AZA = azathioprine; MTX = methotrexate

Table 3. Observed and expected deaths by age and standardized mortality ratios for SECURE-IBD^a Cohort versus China and Italy^b (IBD overall)

Age (years)	SECURE-IBD (n)	SECURE-IBD observed number of deaths	SECURE-IBD fatality rate (%)	China case fatality rate (%)	China expected number of deaths	Italy case fatality rate (%)	Italy expected number of deaths
0-9 years	3	0	0.0%	0	0	0	0
10-19 years	26	0	0.0%	0.2	0.052	0	0
20-29 years	116	0	0.0%	0.2	0.232	0	0
30-39 years	108	1	0.9%	0.2	0.216	0.3	0.324
40-49 years	95	2	2.1%	0.4	0.38	0.4	0.38
50-59 years	74	2	2.7%	1.3	0.962	1	0.74
60-69 years	54	3	5.6%	3.6	1.944	3.5	1.89
70-79 years	24	2	8.3%	8	1.92	12.8	3.072
>=80 years	23	6	26.1%	14.8	3.404	20.2	4.646
All	523	16		2.3	9.11	7.2	11.052
SMR (96% CI)					1.76 (0.90-2.62)		1.45 (0.74-2.16)

^aSECURE-IBD = Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease

^bBased on references 23 and 2, respectively

Table 4. Observed and expected deaths by age and standardized mortality ratios for SECURE-IBD^a Cohort versus United States^b (IBD overall)

Age (years)	SECURE-IBD (n)	SECURE-IBD observed number of deaths	United States case fatality rate (%)	United States expected number of deaths
0-14 years	10	0	0	0
15-44 years	295	1	0.2	0.052
45-64 years	149	5	0.2	0.232
65+ years	69	10	0.2	0.216
All	523	16	0.4	0.38
SMR (95% CI)				1.66 (0.85-2.47)

^aSECURE-IBD = Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease

^bBased on references 24 and 25

Table 5. Multivariable regression for primary and secondary outcomes from SECURE-IBD cohort

Variable (Referent group) ^a	ICU/Vent/Death Odds Ratio (95% CI) (n = 517)	p	Hospitalization or Death Odds Ratio (95% CI) (n = 517)	p	Death Odds Ratio (95% CI) (n = 513)	p
Age	1.04 (1.01-1.06)	0.002	1.03 (1.01-1.04)	<0.001	1.07 (1.03-1.11)	<0.001
Male (Female ^b)	1.20 (0.55-2.60)	0.65	1.38 (0.89-2.15)	0.15	2.78 (0.76-10.14)	0.12
Diagnosis Crohn's disease (ulcerative colitis/IBD unspecified)	0.76 (0.31-1.85)	0.54	0.84 (0.51-1.38)	0.49	1.64 (0.42-6.43)	0.48
Disease severity ^c (remission) Active disease	1.14 (0.49-2.66)	0.76	1.96 (1.23-3.11)	0.005	0.97 (0.26-3.62)	0.96
Systemic corticosteroid (none)	6.87 (2.30-20.51)	<0.001	6.46 (2.74-15.23)	<0.001	11.62 (2.09-64.74)	0.005
TNF antagonist (none)	0.90 (0.37-2.17)	0.81	0.60 (0.38-0.96)	0.03	0.99 (0.23-4.23)	0.99
Current smoker	0.55 (0.06-4.94)	0.59	2.38 (0.92-6.16)	0.07	1.47 (0.12-17.53)	0.76
BMI ≥ 30	2.00 (0.72-5.51)	0.18	1.18 (0.61-2.31)	0.63	1.58 (0.28-8.80)	0.60
Comorbidities (none)						
1	1.22 (0.45-3.26)	0.70	1.29 (0.76-2.20)	0.34	1.64 (0.35-7.67)	0.53
≥2	2.87 (1.05-7.85)	0.04	4.42 (2.16-9.06)	<0.001	2.51 (0.56-11.24)	0.23
5-ASA/sulfasalazine (none)	3.14 (1.28-7.71)	0.01	1.77 (1.00-3.12)	0.05	1.71 (0.46-6.38)	0.43

^aWe adjusted each odds ratio for all other variables listed in this table.

^bOther sex excluded from analysis due to low numbers

^cBy physician global assessment (PGA) at time of COVID-19 infection

Abbreviations: SECURE-IBD = Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease; TNF = Tumor Necrosis Factor; 5-ASA = 5-aminosalicylate

FIGURE LEGEND

Figure 1. World map depicting cases of COVID-19 among patients with inflammatory bowel disease reported to the SECURE-IBD^a database

Footnote:

Interactive web-based map: <http://covidibd.org/map/>

^aSECURE-IBD = Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease

Figure 2. United States map depicting cases of COVID-19 among patients with inflammatory bowel disease reported to the SECURE-IBD^a database

Footnote:

Interactive web-based map: <http://covidibd.org/map/>

^aSECURE-IBD = Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*


	Item No	Recommendation
<input checked="" type="checkbox"/> Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
<input checked="" type="checkbox"/> Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
<input checked="" type="checkbox"/> Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
<input checked="" type="checkbox"/> Study design	4	Present key elements of study design early in the paper
<input checked="" type="checkbox"/> Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
<input checked="" type="checkbox"/> Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed
<input checked="" type="checkbox"/> Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
<input checked="" type="checkbox"/> Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
<input checked="" type="checkbox"/> Bias	9	Describe any efforts to address potential sources of bias
<input checked="" type="checkbox"/> Study size	10	Explain how the study size was arrived at
<input checked="" type="checkbox"/> Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
<input checked="" type="checkbox"/> Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses
Results		
<input checked="" type="checkbox"/> Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers

		potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
<input checked="" type="checkbox"/> Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
		(c) Summarise follow-up time (eg, average and total amount)
<input checked="" type="checkbox"/> Outcome data	15*	Report numbers of outcome events or summary measures over time
<input checked="" type="checkbox"/> Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
<input checked="" type="checkbox"/> Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
<input checked="" type="checkbox"/> Key results	18	Summarise key results with reference to study objectives
<input checked="" type="checkbox"/> Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
<input checked="" type="checkbox"/> Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
<input checked="" type="checkbox"/> Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
<input checked="" type="checkbox"/> Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based


*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

Journal Pre-proof



Journal Pre-proof



Journal Pre-proof

Supplementary Appendix

Table S1. Number of cases reported to the SECURE-IBD^a database by country

Country	Number of cases
Australia	3
Austria	8
Bahrain	1
Belgium	19
Brazil	7
Bulgaria	1
Canada	10
China	1
Croatia	1
Czech Republic	4
Finland	1
France	52
Germany	10
Greece	2
Hungary	1
India	1
Iran, Islamic Republic of	3
Ireland	4
Israel	11
Italy	39
Japan	1
Malaysia	1
Netherlands	17
New Zealand	1
Norway	2
Portugal	8
Qatar	2
Serbia	1
Spain	88
Switzerland	16
Turkey	4
United Arab Emirates	1

^aSurveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease

Table S2. Number of cases reported to the SECURE-IBD^a database by state

State	Number of cases
California	9
Connecticut	7
District of Columbia	2
Florida	4
Georgia	2
Illinois	13
Indiana	2
Louisiana	8
Maine	2
Maryland	2
Massachusetts	7
Michigan	5
Minnesota	1
Mississippi	2
Missouri	4
Montana	1
Nebraska	1
New Jersey	12
New York	71
North Carolina	2
Ohio	1
Oklahoma	1
Pennsylvania	8
Tennessee	2
Utah	1
Virginia	1
Washington	2
Wisconsin	3

^aSurveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease

Table S3. Description of deaths reported to SECURE-IBD cohort^a

Age group	Sex	Diagnosis	Disease activity	Medications	Comorbidities	Hospital stay?	ICU?	Ventilator use?
>=80 years	Male	Ulcerative colitis	Mild	Mesalamine	Cardiovascular disease, Alzheimer	Yes	No	No
>=80 years	Male	Crohn's disease	Remission	Adalimumab	Cardiovascular disease	No	Unknown	Unknown
40-49 years	Male	Ulcerative colitis	Severe	Prednisone or prednisolone, JAK inhibitor	None reported	Yes	Yes	Yes
70-79 years	Male	Ulcerative colitis	Remission	Mesalamine	Cardiovascular disease, Diabetes, COPD, Hypertension, Cancer, Chronic liver disease	Yes	No	No
50-59 years	Male	Crohn's disease	Remission	Adalimumab, Methotrexate	None reported	Yes	No	No
>=80 years	Male	Crohn's disease	Mild	None reported	Cardiovascular disease, Hypertension, Chronic renal disease	Yes	No	No
30-39 years	Female	Crohn's disease	Mild	Adalimumab, Azathioprine, Prednisone or prednisolone	Familial mediteranean fever, juvenile rheumatoid arthritis	Yes	Yes	Yes
>=80 years	Female	Ulcerative colitis	Remission	Mesalamine	Cardiovascular disease, epilepsy, recent orthopedic surgery	Yes	No	No
>=80 years	Male	Ulcerative colitis	Remission	Mesalamine	Cardiovascular disease, COPD, Hypertension, Current cigarette smoker	Yes	No	No
>=80 years	Female	Ulcerative colitis	Severe	Mesalamine, Prednisone or prednisolone	Hypertension	Yes	No	No
60-69 years	Male	Ulcerative colitis	Moderate	Mesalamine	Cancer	Yes	No	No
70-79 years	Male	Ulcerative colitis	Mild	Prednisone or prednisolone	Cardiovascular disease, Hypertension, CMV infection	Yes	No	No
60-69 years	Male	Ulcerative colitis	Unknown	Mesalamine, Azathioprine	Cardiovascular disease, Diabetes, Hypertension	Yes	Yes	Yes
40-49 years	Female	Crohn's disease	Remission	None reported	Asthma	Yes	Yes	Yes
60-69 years	Female	Ulcerative colitis	Remission	Sulfasalazine, Budesonide	None reported	Yes	Yes	Yes
50-59 years	Male	Ulcerative colitis	Remission	Mesalamine	None reported	Yes	Yes	Yes

^aNote that one of these deaths was described in a previous case report¹

Abbreviations: SECURE-IBD = Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease; Meds = medications

Table S4. Acknowledgement of additional organizations who supported or promoted the SECURE-IBD^a database

Professional organization
Agrupación Chilena de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (ACTECCU)
American College of Gastroenterology (ACG)
American Gastroenterological Association (AGA)
Asia-Pacific Association of Gastroenterology (APAGE)
BRICS IBD Consortium
Canadian Association of Gastroenterology
Crohn's and Colitis Australia (CCA)
Crohn's and Colitis Canada (CCC)
Crohn's and Colitis India (CCI)
Crohn's and Colitis New Zealand (CCNZ)
Grupo Argentino de Estudio de Enfermedad de Crohn y Colitis Ulcerosa
Grupo de Estudio de Crohn y Colitis Colombiano
Grupo de Estudos de Doença Inflamatória Intestinal do Brasil (GEDIIB)
Grupo uruguayo de trabajo en enfermedad inflamatoria intestinal (GUTEII)
Grupo Venezolano de Trabajo en Enfermedad Inflamatoria Intestinal
Hong Kong IBD Society (HKIBS)
Improve Care Now (ICN)
Indian Society of Gastroenterology
Japanese IBD Society
Korean Society for the Study of Intestinal Diseases
Malaysia Society of Gastroenterology
National Taiwan GI society
Pediatric Inflammatory Bowel Disease Network (PIBD-NET)
Taiwan IBD society
The Gastroenterological Society of Australia (GESA)
The New Zealand Society of Gastroenterology (NZSG)
United European Gastroenterology (UEG)

^aSurveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease

References

1. Mazza S, Sorce A, Peyvandi F, Vecchi M, Caprioli F. A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis. *Gut*. 2020:gutjnl-2020-321183.

Journal Pre-proof

WHAT YOU NEED TO KNOW

BACKGROUND AND CONTEXT: The impact of Coronavirus disease 2019 (COVID-19) on patients with inflammatory bowel disease (IBD) is unknown. We sought to characterize the clinical course of COVID-19 among IBD patients.

NEW FINDINGS: Of 525 reported cases, 31% were hospitalized and 3% died. Risk factors for severe COVID-19 included increasing age, other comorbidities, systemic corticosteroids, and sulfasalazine/5-aminosalicylate use but not anti-TNF antagonist treatment.

LIMITATIONS: Possibility of reporting bias and unmeasured confounding.

IMPACT: Maintaining remission with steroid-sparing treatments is important in managing IBD patients through this pandemic. TNF antagonist therapy does not appear to be a risk factor for severe COVID-19.

LAY SUMMARY

We created an international registry of IBD patients who developed COVID-19. Corticosteroids, but not TNF antagonists, were associated with adverse outcomes. Other risk factors were similar to the general population.

Journal Pre-proof